Recent Analysts’ Ratings Changes for Oruka Therapeutics (ORKA)

Several brokerages have updated their recommendations and price targets on shares of Oruka Therapeutics (NASDAQ: ORKA) in the last few weeks:

• 10/27/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 10/27/2026 – Oruka Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $165.00 price target on the stock.
• 10/26/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $200.00 price target on the stock.
• 10/19/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $151.00 price target on the stock.
• 10/13/2026 – Oruka Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/7/2026 – Oruka Therapeutics had its “overweight” rating reaffirmed by Piper Sandler.
• 9/24/2026 – Oruka Therapeutics was given a new $120.00 price target by Wedbush.
• 9/24/2026 – Oruka Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $165.00 price target on the stock.
• 9/24/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $96.02 on Friday. Oruka Therapeutics, Inc. has a one year low of $25.23 and a one year high of $115.51. The business’s 50-day moving average price is $88.09 and its two-hundred day moving average price is $70.22. The company has a market capitalization of $6.36 billion, a P/E ratio of -47.30 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 179,950 shares of company stock valued at $16,492,680. 23.49% of the stock is currently owned by corporate insiders.

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.